EAI-045 Property

Density 

1.546±0.06 g/cm3(Predicted)

storage temp. 

2-8°C

solubility 

≥38.3 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH

form 

solid

pka

7.20±0.50(Predicted)

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

EAI-045 Chemical Properties,Usage,Production

Description

EAI045 is a potent and selective inhibitor of mutant EGF receptors (EGFRs; IC₅₀s = 0.076, 0.049, 0.002, and 1.6 μM for recombinant EGFR^L858R, EGFR^T790M, EGFR^L858R/T790M, and wild-type EGFR, respectively). It inhibits phosphorylation of EGFR in a concentration-dependent manner in H1975 cells. EAI045 (0.01-10 μM) reduces proliferation of Ba/F3 cells expressing EGFR^L858R/T790M and EGFR^{L858R/T790M/I941R}. In vivo, EAI045 induces tumor regression and reduces EGFR signaling in mice bearing EGFR^L858R/T790M, EGFR^{Exon19del/T790M}, and EGFR^{L858R/T790M/C797S} tumors when administered at a dose of 60 mg/kg per day in combination with cetuximab.

Description

EAI045 is a potent and selective EGFR inhibitor (fourth generation). EAI045 targets selected drug-resistant EGFR mutants without affecting the wild-type receptor. EAI045 inhibits L858R/T790M-mutant EGFR with low-nanomolar potency in biochemical assays. Therefore, it is a potential candidate drug for the treatment of related non-small cell lung cancer (NSCLC). It should be noted that EAI-045 is effectively in targeting the EGFR C797S mutation, which is resistance to the third-generation EGFR inhibitors including AZD9291 (osimertinib) and CO-1686 (rociletinib).

Uses

Epidermal growth factor receptor (EGFR) is a cell surface receptor often mutated in cancer cells. α-?(5-Fluoro-?2-?hydroxyphenyl)?-?1,?3-?dihydro-?1-?oxo-?N-?2-?thiazolyl-2H-?isoindole-?2-?acetamide is an allosteric EGFR inhibitor that is selective against drug-resistant EGFR mutants.

References

Wang, S., Y. Song, and D. Liu. "EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance." Cancer Letters385(2017):51.
Jia, Y., et al. "Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors:." Nature 534.7605(2016):129.